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 ABSTRACT 
 
Introduction: In stent restenosis (ISR) remains a major public health concern with an increased 
morbidity, mortality and health-related costs. Drug-eluting stents (DES) have reduced ISR, but 
are associated with healing-related issues or hypersensitivity reactions, leading to an increased 
risk of late acute stent thrombosis. Evaluations of new DES are based on animal models or in 
vitro release systems which show several limitations. The role of flow and shear stress on 
endothelial cell and ISR has also been emphasized. The aim of this work was to design and first 
evaluate an original bioreactor, reproducing ex vivo hemodynamic and biological conditions 
similar to human conditions, to further evaluate new DES. 
Methods & Results: This bioreactor was designed to study up to 6 stented arteries connected in 
bypass, immersed in a culture box, in which circulated a physiological systolo-diastolic resistive 
flow. Two centrifugal pumps drove the flow. The principal pump generated pulsating flows by 
modulation of rotation velocity, and the second pump worked at constant rotation velocity, 
ensuring the counter pressure levels and backflows. The flow rate, the velocity profile, the arterial 
pressure and the resistance of the flow were adjustable. The bioreactor was placed in an incubator 
to reproduce a biological environment. A first experience of feasibility was realized over a period 
of 24 days. Three rat aortic thoracic arteries were placed into the bioreactor, immersed in cell 
culture medium change every 3 days, and with a circulating systole diastolic flux circulating 
among the entire experimentation. There was no infection, no leak. At the end of 
experimentation, a morphometric analysis was performed confirming the viability of the arteries.   
Conclusion: We design and patent an original hemodynamic ex vivo model to further study new 
DES and ISR. We will next validate this ex vivo model of ISR reproducing this experimentation 
with stented arteries. Once validated, this bioreactor will allow characterization of the velocity 
field and drug transfers within a stented artery with new functionalized DES, with experimental 
means not available in vivo. Another main point will be the reduction of animal experimentation, 
and the availability of first results of new DES in human tissues (human infra popliteal or 
coronary arteries collected during human donation). 
 
 INTRODUCTION 
 
Percutaneous interventions with stent implantation are now well recognized as the treatment of 
choice for dilation of flow-limiting coronary and peripheral atherosclerotic stenosis. However, 
there are drawbacks to coronary or peripheral stenting, with in stent restenosis (ISR) being the 
Achilles’ heel, accounting for a rate of failure up to 15 to 25% at 6 month for coronary 
pathology1, and up to 50% in infrapopliteal arteries2,3. ISR is a chronic mechanism related to an 
excessive healing of the arterial wall after stent implantation, considered to be a response to 
traumatic injury. It is essentially due to vascular smooth muscle cell (VSMC) proliferation and 
migration, and excessive extracellular matrix production, leading to excessive neointima 
formation involving a recurrence of the symptoms and a new intervention for the patient4. 
 
Drug-eluting stents (DES) have revolutionized the field of percutaneous coronary interventions 
by reducing restenosis rates to less than 10%5,6. DES systems combine mechanical and 
pharmacological approaches, by releasing locally highly cytotoxic (paclitaxel) or cytostatic 
(sirolimus or rapamycin) drugs via a permanent polymer. However, their use causes a delay of 
healing of the vessel wall associated with impairment of the endothelium function and 
hypersensitivity reactions induced by polymers that increases the risk of late acute stent 
thrombosis7. Despite a decrease of reintervention for ISR observed, morbidity and mortality are 
not significantly reduced by the employment of the first generation of DES8. Recently, a new 
generation of DES integrating adsorbable polymers (PLLA) and less toxic drugs (everolimus, 
biolimus, etc..) appears. Clinical trials have demonstrated that the second-generation DES is 
superior to the first-generation in terms of safety and efficacy9. Nevertheless, vascular responses 
to theses stents remain unclear and long term safety of their utilisation is still under 
investigation10. Thus, ISR and late acute thrombosis following stent implantation remain frequent 
clinical and societal concerns and are therefore under extensive investigation.  
 
Currently, evaluations of DES are based on animal models or in vitro release systems which 
show several limitations. Animal models of stenting probably predict human responses but the 
temporal response to healing is characteristically different, as it’s substantially prolonged in 
humans11. For instance, the inability to perform regular tissue and blood samples in vivo makes 
very difficult the evaluation of the drug release, the tissue distribution, and the degradation of the 
polymer. Moreover, the role of the flow on endothelial cell, on the drug elution and on the re-
endothelialisation has been emphasized. Low or high wall shear stresses play a main role in the 
development of atherosclerotic plaque and arterial remodeling12, and the altered hemodynamics 
with abnormal shear stresses on endothelial cells, generated by the stent presence, is an important 
stimulus to ISR13.  
 
From our knowledge, any ex vivo model is currently available to evaluate coated stent efficiency 
in near physiological human conditions. Therefore, the original development of an ex vivo 
bioreactor to do it, will be undoubtedly a real tool for researchers and for all vascular companies 
marketing DES. The goal of this bioreactor is to allow characterization of the velocity field, drug 
release kinetic and the polymer degradation within stented arteries with DES, with experimental 
means not available in vivo. It will also reduce animal experimentation and will provide first 
results in human arteries (infra-popliteal or coronary arteries collected during human donation 
and used in the bioreactor after stenting). 
  
The aim of this work was to design and first evaluate the feasibility of an original bioreactor, 
reproducing ex vivo hemodynamic (resistive systolo-diastolic flow) and biological conditions 
similar to human conditions.  
 
MATERIAL AND METHODS 
 
1. Design of the bioreactor 
The bioreactor was designed to generate various pulsatile flows in a large range of biological 
conditions, with a physiological resistive systolo-diastolic flow circulating simultaneously in up 
to 6 arteries. The flow rate, the velocity profile, the arterial pressure and the resistance of the flow 
can be settled according to the type of artery studied (coronary arteries or infra-popliteal arteries) 
or according to the physiological conditions (hypertension...).  
1.1 Schematic circuit of the bioreactor 
The hydraulic circuit is presented schematically figure 1. Its originality lied in two centrifugal 
pumps which drove the flow. The principal pump (1) generated pulsating flows by modulation of 
rotation velocity. Its inlet was connected to a reservoir of liquid (3). The arteries were placed in a 
culture box (4). The reservoir and the culture box (4) were not sealed to enable gas exchanges 
with the environment. It is known that a centrifugal pump only works following its own 
characteristic of pressure versus flow rate14. Since the flow to settle depends on the arteries 
studied, the pump could produce excess of fluid which was bypassed to the reservoir by a diverter 
(7). The second pump (2), worked at constant rotation velocity, ensuring the counter pressure 
levels and backflows if they are desired. In particular cases (coronary arteries) the second pump 
was not compulsory and the valve (8) was sufficient to set the impedance of the circuit.  
 
Figure 1: Schematic of the bioreactor. 1- Pulsatile pump. 2- Static counter pressure pump. 3-
 Reservoir. 4- Stented arteries in a culture box. 5- Pressure transducer. 6- Flow rate transducer. 7- 
Bypass valve.  8- Counter pressure valve. 
 
1.2 Non-dimensional characteristics of the pump 
The non-dimensional characteristics of the pump are shown in Fig. 2a. The flow-rate coefficient 
(Φ) and pressure rise coefficient (Ψ) were defined respectively by equations 1 and 2. The 
volumetric flow rate is qv, ω the rotational velocity, Rext the diameter of the rotor of the pump, Δp 
the rise of pressure between inlet and outlet and ρ the density of the fluid. In this equations, a 
variation of ω produce a variation in qv and Δp. The principle of the system was to set the 
appropriate law of ω(t) to produce the law of  Δp(t). The driving of the pump was ensuring by a 
brushed DC permanent magnet motor. The basic equations of this motor are U=E+rI, E=Ke*ω 
and I=Kc*C where U is the supply voltage, E the electromotive force, r the internal resistivity, I 
the current intensity, C the torque, specific Ke and Kc constants. To change ω, it was necessary to 
modify E and therefore the supply voltage U. Figure 2b shows that the shape of the pressure 
function produced by the pump was almost similar to the tension U(t) imposed to the motor. It 
was then relatively straightforward to set the pressure parameters of the essay using a black-box 
approach modifying the shape, the aspect ratio, the offset of the tension command. To obtain the 
flow rates observed in a body, the impedance of the arteries circuit was set by counter pressure 
devices (a secondary pump and a valve). 
 (1),    (2),
 
Figure 2a: Centrifugal Pumps caracteristic. 
Pressure rise coefficient Φ vs. flow-rate 
coefficient Ψ 
 
Figure 2b: Law of the tension motor supply 
and law of the pressure over time at the 
outlet of the pump. 
 
1.3 Flow Conditions 
The flow conditions were monitored by a pressure transducer JUMO MIDAS SI 401006 and a 
turbine flow rate sensor Gems FT-110, respectively upstream and downstream the arteries. This 
setup was placed in an incubator. The biological sustainabilyty of the transducers was tested with 
success. However the flow rate transducer was not employed in his fully metrological range, 
more specially when a zero flow rate was set in diaslole part of the cycle. In this conditions, the 
mean flow rate given by the transucer after integration of the signal was compared with series of 
volumetric measurements over 100 cycles. The maximum discrepency reaches 3%. 
 
2. Biological experimentation 
2.1 Ex vivo assay  
All animal experiments were performed by a single operator and all study protocols were 
approved by our local Institutional Animal Care and Use Committee (N°CEEA 212011).   
Three adult male Wistar rats (350 to 400g, Charles River, France) were anesthetized (ketamine 
130 mg/kg and xylazine 14 mg/kg intraperitoneally) and a sternotomy was performed. The 
descending aorta was controlled and intercostal arteries were individually ligated with 8/0 
sutures. The thoracic aorta arteries were removed, gently rinsed with saline. Under a laminar flow 
hood, arteries were immersed in culture medium (blending of Smooth Muscle Cell Growth 
Medium and Endothelial Cell Growth Medium (PromoCell GmbH, Heidelberg, Germany), 
supplemented with penicillin-streptomycin (50 UI/mL)) and connected in bypass in the 
bioreactor. Once the arteries connected, Smooth Muscle Cell Growth Medium (PromoCell 
GmbH, Heidelberg, Germany) with 40% of glycerol to reproduce the blood viscosity15, 
supplemented with penicillin-streptomycin (50 UI/mL) was put into circulation in the circuit, 
according to established resistive systolo-diastolic flow. The bioreactor was placed in an 
incubator, in 37°C and in a 5% CO2 / 95% air atmosphere. The culture medium was replaced 
every 3 days under the laminar flow hood, thanks to a detachable cell culture flask. After 24 days 
of experimentation, the arteries were removed and proceed for histomorphological analysis. 
 
2.2 Histomorphological analysis 
Similarly to the procedure previously described16, arteries were fixed in 4% paraformaldehyde 
phosphate-buffered solution, dehydrated, and embedded in methylmethacrylate polymer 
(Technovit 9100 new, Heraeus, Germany). Sections 60µm thick were cut along the entire 
embedded vessels. Sections were stained with Mayer hematoxylin and eosin, mounted on a glass 
slide and examined under light microscopy (Leika DMIL, Germany) with magnificence of 5. 
Images were digitized and recorded with the use of a video camera (AxioCam ERc 5s, Carl Zeiss 
Microscopy, Germany). For each vessel, 10 sections along the entire length were randomly 
chosen for a histo-morphometric analysis, performed with a computerized digital microscopic 
planimetry algorithm (bioquant program). 
 
RESULTS 
 
1.1 Mechanical feasibility 
All the circuit was built out of biologically compatible materials saying PMMA or equivalent, 
silicon rubbers and stainless steel components. The biological sustainability was tested with 
success over 24 days. Figure3 shows some details of the realization of the pump, the reservoir, 
the arteries connected and the culture box. 
 
Figure 3: Bioreactor with polymeric arteries. A: centrifugal pump; B: circulating fluid reservoir 
allowing changes in flow; C: Container of tissue culture with 6 arteries connected in derivation; 
D: Tissue culture container and its lid with the anti-overflow system to stop the pump in case of 
leak. 
 
1.2 Hemodynamic measurements 
For detailed hemodynamic measurements, the bioreactor was fited with three constant circular 
tube section of silicone rubber of internal diameter D=2.2mm. The fluid was Newtonian as 
considered for blood in this case of diameter17. The medium was mixed with 40% of glycerol to 
reproduce the blood viscosity of μ=3,5 mPa.s at body temperature and density ρ=1050 kg.m-3. An 
example of pulsating flow conditions used for validation is detailed in Table 1. The mean flow 
rate qvmax was given in milliliters per minute (ml/min); Vmax was the maximum velocity in 
centimeters per second (cm/s). The Reynolds number, Re representing the ratio of inertial to 
forces to viscous forces was given by: Re = ρVmax.Dμ–1. The Womersley number, α, expressed 
the pulsating flow frequency in relation to viscous effects; it was defined by α = R(Ω ρμ–1)0.5, 
where R is the artery radius in m, and Ω the pulsation frequency of the flow in rad.s–1. A 
representative cycle of intra-arterial flow-rate and operating pressure is given in Figure 4. The 
measured confirmed the standard velocity characteristics of the flow, and particularly, a resistive 
flow as describe in human muscular arteries (zero-flow imposed during a part of diastole)18.  
parameters value unit 
D 2.2 mm 
Δp min/max 85-130 mmHg 
qv 0-110 ml/min 
V_max 0-48 cm/s 
μ 3.5 N.s.m–2 
Re 320 - 
f 70 Cycle/s 
α 1.63 - 
Table 1: flow conditions in feasibility testing. D: internal diameter; p: pressure; qv: mean flow 
rate; Vmax: maximum velocity; μ: blood viscosity; Re: Reynolds number; f: frequencies ; α: 
Womersley number; 
 
   
Figure 4: Pressure at the inlet and Flow at the outlet of arteries over time; point A: peak systolic 
flow; point B: flow at the end of diastole, a zero-flow imposed in condition of a muscular human 
leg artery. 
 
 1.2 Biological evaluation 
The bioreactor, with the 3 rat aorta branched in a bridged tap, has been functional during the 
experimentation (24 days). A systolo diastolic flux, with a systolic arterial pressure of 100 mmHg 
and a diastolic arterial pressure of 60 mmHg, has circulated in the bioreactor during the 24 days. 
There was no leak and no bacterial infection in the bioreactor. The histomorphological analysis of 
the arteries showed no evidence of abnormality or infection. (Figure 5).  
 
 
DISCUSSION 
 
We elaborated and patent19 an ex-vivo bioreactor, to study stented arteries with drug eluting stent 
during a prolonged period, in biological and hemodynamical conditions close to those of life. We 
demonstrated that we reproduced a resistive systolo-diastolic flux in the circuit, similar to those 
of peripheral muscular arteries. The attractive feature of this system is based on the possibility to 
control and adjusts the bioreactor conditions on demand to match the type of arteries conditions. 
We also demonstrated in this work the feasibility of this experimentation, by maintaining arteries 
alive in the bioreactor during 24 days without tissue infection. 
 
Ex vivo engineering of living tissues is a rapidly developing area with the potential to impact 
significantly on a wide-range of biomedical applications. By enabling reproducible and 
controlled changes of specific environmental factors, bioreactor systems provide both the 
technological means to reveal fundamental mechanisms of cell function in a 3D environment, and 
the potential to improve the quality of engineered tissues20. 
 
Figure 5: morphological analysis of a 
rat aorta section, removed after 24 days 
in the bioreactor. 
The aim of our original bioreactor is to overcome the drawbacks of animal models to study ISR 
and DES. Animal models of stenting probably predict human responses, as the stages of healing 
are similar, but the temporal response to healing is characteristically different, and is substantially 
prolonged in humans. One obvious explanation for this is the underlying atherosclerotic process 
in human. The absence of atherosclerotic disease is likely to contribute to a more predictable 
healing response in animals. In contrast, in diseased human coronary arteries, at least 70% of the 
stent is in direct contact with the underlying atherosclerotic plaque. Furthermore, rather than a 
simple proliferative response, smooth muscle cell migration from within the plaque or media to 
the expanding neointima may be the more dominant in human11. In our bioreactor, human arterial 
tissue will be used to assess the new DES and obtain first results of efficiency in human. 
 
Another weakness of the animal models is the inability to perform regular tissue and blood 
samples that makes very difficult the evaluation of kinetic characteristics of drug eluting stent 
(kinetic of the drug release, tissue distribution of drug and degradation of the polymer). Our 
bioreactor allows performing a detailed characterization of the drug transfers within a stented 
artery with DES. The associated velocity fields as well the shear stresses are easy to reach. At 
least, animal experimentation is ethically controversial and must be limited to minimum. 
 
To our knowledge, only a static ex vivo model of ISR has been described in literature. It consists 
on internal mammary arteries from atherosclerotic patients stented and maintained in culture for 
0–28 days21. Nevertheless, Samady et al 12 emphasized the major role of biomechanical factors 
and wall shear stress (WSS) to human coronary atherosclerotic plaque progression and 
transformation. They demonstrated that coronary segments with low WSS in patients with 
coronary arterial disease developed greater plaque area progression over a relatively short time 
interval (6 months) compared with segments located in areas with intermediate and high WSS. 
Compared with intermediate-WSS segments, low-WSS segments developed progression of 
plaque and necrotic core area, whereas high-WSS segments had progression of necrotic core and 
dense calcium and regression of fibrous and fibro fatty tissue. In vitro and animal studies have 
also demonstrated that low WSS promotes atherosclerosis development through loss of the 
physiological flow-oriented alignment of the endothelial cells, increasing low-density lipoprotein 
accumulation, proliferation of smooth muscle cells, transmigration of macrophages, and 
inflammation; impairing nitric oxide–dependent atheroprotection; and promoting oxidative 
stress22,23. Nonlaminar shear stress, such as might be present after vessel injury like stenting, 
results in ERK1/2 activation from both PDGF-BB and interleukin-1, and results in SMC 
chemotaxis and proliferation24,25. Moreover, in our experience with static culture of stented 
human infra-popliteal arteries, no ISR was depicted (personal data unpublished). Thus a static 
model of ISR seems inappropriate.  
 
Two other bioreactors are patented. One model is design for ex vivo hemodynamic assessment of 
wall shear stress after stenting26. It reproduces a sinusoidal flux during short experimentations. 
The other model is design for the assessment of drug scattering27. It contains a peristaltic pump 
and several benches. Our bioreactor is designed for the assessment of drug scattering and efficacy 
in biological tissues during long term experimentations. The circulating flux is a resistive systolo-
diastolic flux, more similar to the one in infrapopliteal arteries. Our bioreactor will lead to a 
better understanding of the relationship between ISR and shear stress then providing a convenient 
tool for the ex-vivo evaluation of the efficacy of DES. 
 
Limitations 
These are first results evaluating our bioreactor. Currently we only demonstrated the feasibility of 
hemodynamic simulation of arterial resistive blood flow, and the proper functioning of the 
bioreactor in biological conditions. Further investigations are required to assess the reproduction 
of in stent restenosis ex vivo. 
 
Conclusions 
We developed, patent and first evaluate an original hemodynamic ex vivo model to assess in stent 
restenosis and new drug eluting stents. Further investigations are requires to demonstrate the ex 
vivo reproduction of in stent restenosis. This bioreactor will be a tool of work for researchers and 
companies manufacturing stents and particularly drug eluting stents. Indeed, the latter will be 
used to predict drug release kinetics, to evaluate the relevance and the stability of the polymer 
coating, and to investigate the tissue integration or the therapeutic activity of the coated stents on 
in stent restenosis. Finally, the originality and the added value of this bioreactor consist in 
working with human arteries that ultimately will reduce the animal assays.  
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